Marinus Pharmaceuticals Stock Return On Equity

MRNS Stock

USD 0.32 0.01 3.23%

Marinus Pharmaceuticals fundamentals help investors to digest information that contributes to Marinus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Marinus Stock. The fundamental analysis module provides a way to measure Marinus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marinus Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Return On Equity	(8.43)	(8.01)

Return On Equity is likely to gain to -8.01 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Marinus Pharmaceuticals Company Return On Equity Analysis

Marinus Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Marinus Pharmaceuticals Return On Equity

-29.87

Most of Marinus Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marinus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Marinus Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Marinus Pharmaceuticals is extremely important. It helps to project a fair market value of Marinus Stock properly, considering its historical fundamentals such as Return On Equity. Since Marinus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Marinus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Marinus Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables
Total Assets		0.69	0.55	-0.77	-0.82	0.82	0.74	1.0	0.08	0.67	0.8	0.83	0.86	0.23	0.79	0.93	-0.23	-0.39	0.45	0.94	0.23	0.82
Total Stockholder Equity	0.69		0.45	-0.95	-0.3	0.51	0.07	0.67	-0.48	0.62	0.29	0.65	0.45	-0.21	0.35	0.52	-0.73	-0.02	0.5	0.62	0.45	0.25
Current Deferred Revenue	0.55	0.45		-0.37	-0.56	0.65	0.42	0.54	0.28	0.62	0.56	0.41	0.47	0.42	0.54	0.5	-0.18	-0.21	0.26	0.4	0.16	0.33
Net Debt	-0.77	-0.95	-0.37		0.35	-0.57	-0.19	-0.76	0.47	-0.55	-0.33	-0.6	-0.53	0.32	-0.36	-0.58	0.7	0.2	-0.37	-0.7	-0.42	-0.43
Retained Earnings	-0.82	-0.3	-0.56	0.35		-0.75	-0.92	-0.82	-0.5	-0.62	-0.97	-0.74	-0.91	-0.62	-0.94	-0.9	-0.19	0.5	-0.44	-0.81	-0.13	-0.78
Accounts Payable	0.82	0.51	0.65	-0.57	-0.75		0.66	0.84	0.1	0.71	0.74	0.6	0.73	0.29	0.65	0.79	-0.27	-0.57	0.25	0.69	0.25	0.65
Total Liab	0.74	0.07	0.42	-0.19	-0.92	0.66		0.74	0.63	0.39	0.92	0.56	0.84	0.62	0.86	0.77	0.39	-0.52	0.25	0.76	-0.06	0.91
Total Current Assets	1.0	0.67	0.54	-0.76	-0.82	0.84	0.74		0.11	0.66	0.8	0.83	0.88	0.21	0.78	0.93	-0.2	-0.46	0.46	0.94	0.24	0.81
Short Term Debt	0.08	-0.48	0.28	0.47	-0.5	0.1	0.63	0.11		-0.03	0.51	0.18	0.34	0.73	0.45	0.22	0.89	-0.3	0.21	0.19	-0.29	0.35
Common Stock	0.67	0.62	0.62	-0.55	-0.62	0.71	0.39	0.66	-0.03		0.67	0.66	0.68	0.32	0.7	0.66	-0.35	-0.24	0.25	0.54	0.67	0.35
Property Plant Equipment	0.8	0.29	0.56	-0.33	-0.97	0.74	0.92	0.8	0.51	0.67		0.72	0.91	0.66	0.96	0.85	0.2	-0.46	0.4	0.82	0.18	0.81
Net Tangible Assets	0.83	0.65	0.41	-0.6	-0.74	0.6	0.56	0.83	0.18	0.66	0.72		0.8	0.35	0.78	0.86	-0.06	-0.22	0.78	0.86	0.3	0.53
Long Term Debt	0.86	0.45	0.47	-0.53	-0.91	0.73	0.84	0.88	0.34	0.68	0.91	0.8		0.4	0.91	0.87	0.07	-0.61	0.46	0.89	0.27	0.79
Short Term Investments	0.23	-0.21	0.42	0.32	-0.62	0.29	0.62	0.21	0.73	0.32	0.66	0.35	0.4		0.69	0.38	0.53	0.02	0.29	0.25	-0.21	0.33
Long Term Debt Total	0.79	0.35	0.54	-0.36	-0.94	0.65	0.86	0.78	0.45	0.7	0.96	0.78	0.91	0.69		0.84	0.16	-0.32	0.45	0.8	0.16	0.76
Capital Surpluse	0.93	0.52	0.5	-0.58	-0.9	0.79	0.77	0.93	0.22	0.66	0.85	0.86	0.87	0.38	0.84		-0.07	-0.43	0.5	0.87	0.2	0.73
Short Long Term Debt	-0.23	-0.73	-0.18	0.7	-0.19	-0.27	0.39	-0.2	0.89	-0.35	0.2	-0.06	0.07	0.53	0.16	-0.07		-0.18	0.08	-0.05	-0.38	0.13
Long Term Investments	-0.39	-0.02	-0.21	0.2	0.5	-0.57	-0.52	-0.46	-0.3	-0.24	-0.46	-0.22	-0.61	0.02	-0.32	-0.43	-0.18		-0.09	-0.42	-0.13	-0.46
Net Invested Capital	0.45	0.5	0.26	-0.37	-0.44	0.25	0.25	0.46	0.21	0.25	0.4	0.78	0.46	0.29	0.45	0.5	0.08	-0.09		0.6	-0.01	0.15
Net Working Capital	0.94	0.62	0.4	-0.7	-0.81	0.69	0.76	0.94	0.19	0.54	0.82	0.86	0.89	0.25	0.8	0.87	-0.05	-0.42	0.6		0.2	0.83
Capital Stock	0.23	0.45	0.16	-0.42	-0.13	0.25	-0.06	0.24	-0.29	0.67	0.18	0.3	0.27	-0.21	0.16	0.2	-0.38	-0.13	-0.01	0.2		-0.03
Net Receivables	0.82	0.25	0.33	-0.43	-0.78	0.65	0.91	0.81	0.35	0.35	0.81	0.53	0.79	0.33	0.76	0.73	0.13	-0.46	0.15	0.83	-0.03

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Marinus Pharmaceuticals

Return On Equity Over Time

Marinus Total Stockholder Equity

Total Stockholder Equity

15.93 Million

At this time, Marinus Pharmaceuticals' Total Stockholder Equity is comparatively stable compared to the past year.

Based on the latest financial disclosure, Marinus Pharmaceuticals has a Return On Equity of -29.8655. This is 24.6% higher than that of the Pharmaceuticals sector and 18.09% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Marinus Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marinus Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marinus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Marinus Pharmaceuticals by comparing valuation metrics of similar companies.

Marinus Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Marinus Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Marinus Pharmaceuticals from analyzing Marinus Pharmaceuticals' financial statements. These drivers represent accounts that assess Marinus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Marinus Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	117.4M	117.7M	436.0M	155.5M	584.2M	613.4M
Enterprise Value	49.6M	27.3M	353.8M	(12.4M)	574.0M	602.7M

Marinus Fundamentals

	Return On Equity	-29.87
	Return On Asset	-0.58
	Operating Margin	(3.76) %
	Current Valuation	31.59 M
	Shares Outstanding	55.19 M
	Shares Owned By Insiders	10.94 %
	Shares Owned By Institutions	83.03 %
	Number Of Shares Shorted	5.66 M
	Price To Earning	(4.80) X
	Price To Book	3.17 X
	Price To Sales	0.59 X
	Revenue	30.99 M
	Gross Profit	(55.94 M)
	EBITDA	(125.5 M)
	Net Income	(141.41 M)
	Cash And Equivalents	168.25 M
	Cash Per Share	4.52 X
	Total Debt	110.36 M
	Debt To Equity	0.88 %
	Current Ratio	8.41 X
	Book Value Per Share	0.31 X
	Cash Flow From Operations	(118 M)
	Short Ratio	1.09 X
	Earnings Per Share	(2.47) X
	Target Price	1.47
	Number Of Employees	165
	Beta	1.26
	Market Capitalization	17.79 M
	Total Asset	170.91 M
	Retained Earnings	(571.93 M)
	Working Capital	124.62 M
	Current Asset	57.77 M
	Current Liabilities	7.43 M
	Net Asset	170.91 M

About Marinus Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Marinus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marinus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marinus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Marinus Stock Analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC